Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Chronic administration of Dimebon does not ameliorate amyloid-β pathology in 5xFAD transgenic mice.

Peters OM, Shelkovnikova T, Tarasova T, Springe S, Kukharsky MS, Smith GA, Brooks S, Kozin SA, Kotelevtsev Y, Bachurin SO, Ninkina N, Buchman VL.

J Alzheimers Dis. 2013;36(3):589-96. doi: 10.3233/JAD-130071.

PMID:
23645096
2.

Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model.

Steele JW, Gandy S.

Autophagy. 2013 Apr;9(4):617-8. doi: 10.4161/auto.23487. Epub 2013 Feb 4.

3.

Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease.

Sadleir KR, Eimer WA, Kaufman RJ, Osten P, Vassar R.

PLoS One. 2014 Jul 3;9(7):e101643. doi: 10.1371/journal.pone.0101643. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e110914.

4.

Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice.

Peters OM, Connor-Robson N, Sokolov VB, Aksinenko AY, Kukharsky MS, Bachurin SO, Ninkina N, Buchman VL.

J Alzheimers Dis. 2013;33(4):1041-9. doi: 10.3233/JAD-2012-121732.

PMID:
23099813
5.

1950 MHz Electromagnetic Fields Ameliorate Aβ Pathology in Alzheimer's Disease Mice.

Jeong YJ, Kang GY, Kwon JH, Choi HD, Pack JK, Kim N, Lee YS, Lee HJ.

Curr Alzheimer Res. 2015;12(5):481-92.

6.

Amyloid β Protein Aggravates Neuronal Senescence and Cognitive Deficits in 5XFAD Mouse Model of Alzheimer's Disease.

Wei Z, Chen XC, Song Y, Pan XD, Dai XM, Zhang J, Cui XL, Wu XL, Zhu YG.

Chin Med J (Engl). 2016 Aug 5;129(15):1835-44. doi: 10.4103/0366-6999.186646.

7.

Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice.

Devi L, Ohno M.

Neurobiol Dis. 2012 Jan;45(1):417-24. doi: 10.1016/j.nbd.2011.09.001. Epub 2011 Sep 13.

8.

Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice.

Shelkovnikova TA, Ustyugov AA, Millership S, Peters O, Anichtchik O, Spillantini MG, Buchman VL, Bachurin SO, Ninkina NN.

Neurodegener Dis. 2011;8(6):430-7. doi: 10.1159/000324989. Epub 2011 May 12.

9.

Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer's 5xFAD mice.

Fragkouli A, Tsilibary EC, Tzinia AK.

Neurobiol Dis. 2014 Oct;70:179-89. doi: 10.1016/j.nbd.2014.06.021. Epub 2014 Jul 6.

PMID:
25008761
11.
12.

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E.

J Neurosci Res. 2006 May 15;83(7):1252-61.

PMID:
16511867
13.

Abundance of Aβ₅-x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease.

Guzmán EA, Bouter Y, Richard BC, Lannfelt L, Ingelsson M, Paetau A, Verkkoniemi-Ahola A, Wirths O, Bayer TA.

Mol Neurodegener. 2014 Apr 2;9:13. doi: 10.1186/1750-1326-9-13.

14.

Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer's disease.

Devi L, Alldred MJ, Ginsberg SD, Ohno M.

PLoS One. 2012;7(3):e32792. doi: 10.1371/journal.pone.0032792. Epub 2012 Mar 5.

16.

Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model.

Fang F, Chen X, Huang T, Lue LF, Luddy JS, Yan SS.

Biochim Biophys Acta. 2012 Feb;1822(2):286-92. doi: 10.1016/j.bbadis.2011.10.004. Epub 2011 Oct 12.

17.

Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice.

Bachurin SO, Shelkovnikova TA, Ustyugov AA, Peters O, Khritankova I, Afanasieva MA, Tarasova TV, Alentov II, Buchman VL, Ninkina NN.

Neurotox Res. 2012 Jul;22(1):33-42. doi: 10.1007/s12640-011-9299-y. Epub 2011 Dec 17.

18.

Ferulic acid is a nutraceutical β-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice.

Mori T, Koyama N, Guillot-Sestier MV, Tan J, Town T.

PLoS One. 2013;8(2):e55774. doi: 10.1371/journal.pone.0055774. Epub 2013 Feb 8.

19.

Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice.

Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H.

J Alzheimers Dis. 2009;17(3):681-97. doi: 10.3233/JAD-2009-1071. Erratum in: J Alzheimers Dis. 2009 Nov;18(3):727. Wang, Lilly [corrected to Wang, Li]..

20.

Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.

Hüttenrauch M, Baches S, Gerth J, Bayer TA, Weggen S, Wirths O.

J Alzheimers Dis. 2015;44(4):1291-302. doi: 10.3233/JAD-142463.

PMID:
25408216

Supplemental Content

Support Center